Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Oct 21;13(39):5238-44.
doi: 10.3748/wjg.v13.i39.5238.

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

Renato Caviglia  1 , Mentore Ribolsi, Marina Rizzi, Sara Emerenziani, Maria Laura Annunziata, Michele Cicala
Affiliations

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

Renato Caviglia et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the safety and efficacy of a long-term therapy with infliximab in Crohn's disease (CD) and ulcerative colitis (UC) patients retrospectively.

Methods: The medical charts of 50 patients (40 CD and 10 UC), who received after a loading dose of 3 infliximab infusions scheduled re-treatments every 8 wk as a maintenance protocol, were reviewed.

Results: Median (range) duration of treatment was 27 (4-64) mo in CD patients and 24.5 (6-46) mo in UC patients. Overall, 32 (80%) CD and 9 (90%) UC patients showed a sustained clinical response or remission throughout the maintenance period. Three CD patients shortened the interval between infusions. Eight (20%) CD patients and 1 UC patient underwent surgery for flare up of disease. Nine out of 29 CD and 4 out of 9 UC patients, who discontinued infliximab scheduled treatment, are still relapse-free after a median of 16 (5-30) and 6.5 (4-16) mo following the last infusion, respectively. Ten CD patients (25%) and 1 UC patient required concomitant steroid therapy during maintenance period, compared to 30 (75%) and 9 (90%) patients at enrollment. Of the 50 patients, 16 (32%) experienced at least 1 adverse event and 3 patients (6%) were diagnosed with cancer during maintenance treatment.

Conclusion: Scheduled infliximab strategy is effective in maintaining long-term clinical remission both in CD and UC and determines a marked steroid sparing effect. Long-lasting remission was observed following infliximab withdrawal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients observed at 12-mo intervals (endpoints) during IFX maintenance therapy. A: CD; B: UC. Numbers in boxes refer to patients reaching each endpoint. Numbers in rhombics refer to patients not reaching 12-mo endpoints.
Figure 2
Figure 2
Kaplan-Meier survival curve for CD patients (n = 40). The cumulative probability of being free of relapse in CD patients with complete response was: 97.2% (CI: 91.8%-100%) at 12 mo, 90.3% (CI: 79.7%-100%) at 24 mo, 81.7% (CI: 66.9%-96.5%) at 36 mo, 73.5% (CI: 53.3%-93.7%) at 48 mo, and 61.3% (CI: 33.6%-88.9%) at 51 mo.
See this image and copyright information in PMC

References

    1. Podolsky DK. Inflammatory bowel disease (2) N Engl J Med. 1991;325:1008–1016. - PubMed
    1. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91–96. - PubMed
    1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182–205. - PubMed
    1. Schreiber S. Medical treatment: an overview. In: Satsangi J, editor. Inflammatory Bowel Diseases. London: Churchill Livingstone; 2003. pp. 297–301.
    1. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635–643. - PubMed